Vaxart, Inc. (VXRT) Earnings Call Transcripts

18 earnings calls from August 2022 to November 6, 2026

OTC Pink Market US Health Care Biotechnology

Vaxart, Inc.'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Vaxart, Inc. reported a significant revenue increase to $39.2 million, up from $20.9 million in the same quarter last year, primarily driven by a BARDA contract. The company achieved a net income of $5.2 million, or $0.02 per share, reflecting effective cost management. Management maintained guidance for a cash runway extending into Q2 2027, emphasizing ongoing clinical milestones and operational efficiency as key drivers for future growth.

Reported metrics

MetricValueContext
Revenue $39.2 million (beat) vs $20.9 million last year, +87% YoY
Net Income $5.2 million (beat) vs $2.5 million last year, +108% YoY
EPS $0.02 (beat) vs $0.01 last year, +100% YoY
Cash Position $61 million (positive) vs $50 million last quarter, +22% QoQ
Cash Runway Into Q2 2027 (neutral) Maintained guidance
R&D Expenses Reduced (positive) Compared to Q1 2025

Guidance from management

Vaxart expects its cash runway to extend into Q2 2027, maintaining this guidance while focusing on advancing clinical programs and operational efficiency.

What management said

We've gotten a large number of inquiries from lots of shareholders, and quite a few of them overlapped. So to start, we're putting the questions together according to subject. The first one: many people have been asking about what the main emphasis of the sentinel readout is, and whether that emphasis is safety rather than efficacy; also, questions about whether folks can still expect that readout, since early Q2 has...
— David Carey, Q1 FY2026 earnings call
Alright, thanks James. The following question is also directed at you. Is it Vaxart's view that there will be a significant distinction when it comes to immunogenicity, longevity, and cross-reactivity of the immune response, as well as viral — apologies, better load reduction, that could be observed even within a small cohort?
— David Carey, Q1 FY2026 earnings call

What analysts pressed on

Analysts expressed concerns regarding the delays in the COVID-19 trial data release, questioning if the timeline slipping indicates potential issues with data quality or collection processes. There were also inquiries about the company's ability to secure funding for the norovirus program.

Main topics on the call

Read the full Vaxart, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Vaxart, Inc.

Vaxart, Inc. (VXRT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on OTC Pink Market and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 18 calls on record spanning August 8, 2022 to November 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.

Earnings Call History

EarningsCalls.dev has 18 Vaxart, Inc. earnings call transcripts on record, spanning August 8, 2022 to November 6, 2026. Based on this history, Vaxart, Inc. reports quarterly. The most recent call on file is dated November 6, 2026. The full list is below — each row opens the transcript.

Ticker
VXRT
Exchange
OTC Pink Market
Country
US
Sector
Health Care
Industry
Biotechnology
Calls on record
18
First call
August 8, 2022
Most recent
November 6, 2026
Reporting cadence
quarterly
Quarter Date
Q3 FY2026 Nov 6, 2026 Read transcript →
Q2 FY2026 Aug 7, 2026 Read transcript →
Q1 FY2026 May 8, 2026 Read transcript →
Earnings Calls Mar 12, 2026 Read transcript →
Q3 FY2025 Nov 13, 2025 Read transcript →
Q2 FY2025 Aug 13, 2025 Read transcript →
Q1 FY2025 May 13, 2025 Read transcript →
Earnings Calls Mar 20, 2025 Read transcript →
Q3 FY2024 Nov 13, 2024 Read transcript →
Q2 FY2024 Aug 8, 2024 Read transcript →
Q1 FY2024 May 13, 2024 Read transcript →
Earnings Calls Mar 14, 2024 Read transcript →
Q3 FY2023 Nov 2, 2023 Read transcript →
Q2 FY2023 Aug 3, 2023 Read transcript →
Q1 FY2023 May 4, 2023 Read transcript →
Earnings Calls Mar 15, 2023 Read transcript →
Q3 FY2022 Nov 8, 2022 Read transcript →
Q2 FY2022 Aug 8, 2022 Read transcript →